Meeting
2020 ASCO Virtual Scientific Program
Ibrutinib-based combination therapy exhibited therapeutic benefit in newly diagnosed primary central nervous system lymphoma.
Authors
Feili Chen
Guangdong Provincial People's Hospital, Guangzhou, China
Feili Chen , Diwen Pang , Hanguo Guo , Qiuxiang Ou , Xue Wu , Xinmiao Jiang , Xiaojuan Wei , Sichu Liu , Ling Huang , Zhanli Liang , Wenyu Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 38: 2020 (suppl; abstr 2556)
DOI
10.1200/JCO.2020.38.15_suppl.2556
Abstract #
2556
Poster Bd #
47
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 1B of ibrutinib and high-dose methotrexate for recurrent/refractory CNS lymphoma.
First Author: Christian Grommes
Poster
2023 ASCO Annual Meeting
Final analysis of the phase IB part of the LOC-R01 trial, a non-comparative randomized phase IB/II study of escalating doses of lenalidomide and ibrutinib in association with R-MPV for patients with a newly diagnosed primary central nervous system lymphoma (PCNSL).
First Author: Marion Alcantara
Poster
2016 ASCO Annual Meeting
Phase I study of single agent ibrutinib in recurrent/refractory primary (PCNSL) and secondary CNS lymphoma (SCNSL).
First Author: Christian Grommes
Poster
2013 ASCO Annual Meeting
High-dose methotrexate with and without rituximab for the treatment of newly diagnosed primary CNS lymphoma: Johns Hopkins Hospital experience.
First Author: Matthias Holdhoff